Afectair is a series of proprietary ventilator circuit patient interface connectors, that eases the delivery of any inhaled therapies to critical care patients requiring ventilatory support.
The in-vitro study demonstrated that with the use of Afectair, nitric oxide utilisation requirements to achieve desired inhaled nitric oxide dose decreased by 50 to 70% compared to current standard of care.
The Afectair resulted in as much as a 70% reduction in the amount of nitric oxide required to deliver the desired dose of the therapeutic gas when compared with standard treatment.
Discovery Laboratories R&D senior vice-president Russell Clayton said the results of the study suggest that Afectair has the ability to effectively deliver a medical gas directly to a critical care patient, while reducing the amount of medical gas needed to achieve a target dose.
The company intends to launch Afectair in the US and the European Union in 2012.